Ftse Mib
36.103,87
-0,45%
DAX
20.899,28
0,01%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
106.189,82
2,98%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Verastem Inc (VSTM) Verastem Inc (VSTM) Notizie

Verastem Inc

VSTM
5,36
0,08 (1,52%)
18 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
15/1/202513:30BWVerastem Oncology Names Matthew E. Ros as Chief Operating..
14/1/202522:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/1/202522:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/1/202513:30BWVerastem Oncology Exercises Option Early to License VS-7375,..
13/1/202523:03EDGAR2Form 144 - Report of proposed sale of securities
13/1/202513:36EDGAR2Form 8-K - Current report
13/1/202513:30BWVerastem Oncology Announces Debt Refinancing with Oberland..
08/1/202522:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202513:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
30/12/202422:30BWVerastem Oncology Announces FDA Acceptance and Priority..
26/12/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202413:00GLOBEApplied Therapeutics Appoints John H. Johnson as Executive..
18/12/202413:30BWVerastem Oncology Provides a Clinical Update for RAMP 203..
26/11/202413:00BWVerastem Oncology to Present at the 7th Annual Evercore ISI..
14/11/202421:33EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202415:35EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
08/11/202420:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/11/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/11/202422:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202422:05BWVerastem Oncology Reports Third Quarter 2024 Financial..
31/10/202421:01BWVerastem Oncology Completes Rolling NDA Submission to the..
31/10/202412:30BWVerastem Oncology to Participate in Upcoming Investor..
17/10/202417:50EDGAR2Form 8-K - Current report
17/10/202407:00BWVerastem Oncology Presents Positive Updated RAMP 201 Data..
09/10/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/10/202412:00BWVerastem Oncology Announces Details for the Oral..
07/10/202413:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
24/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/9/202422:05BWVerastem Oncology to Present at the 2024 Cantor Global..
10/9/202413:30BWVerastem Oncology to Present Mature RAMP 201 Data in..
03/9/202413:30BWVerastem Oncology and STAAR Ovarian Cancer Foundation..
08/8/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:05BWVerastem Oncology Reports Second Quarter 2024 Financial..
29/7/202422:01BWVerastem Oncology Receives FDA Orphan Drug Designation for..
25/7/202414:45EDGAR2Form 8-K - Current report
24/7/202423:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
24/7/202405:20BWVerastem Oncology Announces Pricing of $55.0 Million Public..
23/7/202422:33EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
23/7/202422:05BWVerastem Oncology Announces Proposed Public Offering of..
23/7/202422:01EDGAR2Form 8-K - Current report
12/7/202413:30BWVerastem Oncology Announces First Patient Dosed with..
11/7/202413:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/7/202413:30BWVerastem Oncology Announces Inducement Grants Under Nasdaq..
01/7/202413:30BWVerastem Oncology Announces Addition to Russell 3000® and..
Apertura: 5,31 Min: 5,12 Max: 5,42
Chiusura: 5,28

La tua Cronologia

NASDAQ
VSTM
Verastem
AMEX
HIYS
Invesco High Yield Selec...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network